Journal of Clinical and Aesthetic Dermatology

JUN 2017

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/839245

Contents of this Issue

Navigation

Page 24 of 63

25 JCAD journal of clinical and aesthetic dermatology June 2017 • Volume 10 • Number 6 T a b l e 3 . P r e s c r i p t i o n a g e n t a n d o t h e r t r e a t m e n t u t i l i z a t i o n P A T I E N T S , N ( % ) E T R ( N = 4 0 9 ) P P R ( N = 1 9 1 ) N E V E R R A R E L Y S O M E T I M E S O F T E N A L W A Y S N E V E R R A R E L Y S O M E T I M E S O F T E N A L W A Y S Rx topical agents Azelaic acid 361 (88.3) 8 (2.0) 18 (4.4) 11 (2.7) 11 (2.7) 163 (85.3) 4 (2.1) 10 (5.2) 7 (3.7) 7 (3.7) Brimonidine 391 (95.6) 7 (1.7) 6 (1.5) 2 (0.5) 3 (0.7) 184 (96.3) 0 4 (2.1) 1 (0.5) 2 (1.0) Metronidazole 250 (61.1) 23 (5.6) 54 (13.2) 23 (5.6) 59 (14.4) 118 (61.8) 11 (5.8) 25 (13.1) 19 (9.9) 18 (9.4) Ivermectin 404 (98.8) 2 (0.5) 1 (0.2) 1 (0.2) 1 (0.2) 187 (97.9) 0 2 (1.0) 2 (1.0) 0 Rx oral agents Doxycycline 352 (86.1) 15 (3.7) 14 (3.4) 13 (3.2) 15 (3.7) 161 (84.3) 8 (4.2) 13 (6.8) 5 (2.6) 4 (2.1) Other 341 (83.4) 29 (7.1) 27 (6.6) 5 (1.2) 7 (1.7) 156 (81.7) 7 (3.7) 16 (8.4) 6 (3.1) 6 (3.1) Other treatments Sun protection 85 (20.8) 26 (6.4) 92 (22.5) 113 (27.6) 93 (22.7) 39 (20.4) 15 (7.9) 53 (27.7) 45 (23.6) 39 (20.4) OTC cleansers 225 (55.0) 29 (7.1) 45 (11.0) 47 (11.5) 63 (15.4) 74 (38.7) 18 (9.4) 26 (13.6) 35 (18.3) 38 (19.9) Rx cleansers 389 (95.1) 5 (1.2) 6 (1.5) 4 (1.0) 5 (1.2) 178 (93.2) 2 (1.0) 7 (3.7) 3 (1.6) 1 (0.5) Other 362 (88.5) 20 (4.9) 13 (3.2) 10 (2.4) 4 (1.0) 153 (80.1) 7 (3.7) 11 (5.8) 10 (5.2) 10 (5.2) ETR=erythematotelangiectatic rosacea; OTC=over the counter; PPR=papulopustular rosacea; Rx=prescription T a b l e 4 . B e h a v i o r s o f p a t i e n t s d i s s a t i s B e d w i t h t r e a t m e n t a B E H A V I O R , N ( % ) E T R ( N = 6 0 ) P P R ( N = 4 7 ) Did not take treatment as speciBed/skipped treatment 26 (43.3) 20 (42.6) Considered alternative treatment 15 (25.0) 18 (38.3) Continued treatment as speciBed 14 (23.3) 10 (21.3) Fewer reBlls/OTC purchases 11 (18.3) 9 (19.1) Additional visits to a health care professional 8 (13.3) 9 (19.1) None of the above 15 (25.0) 4 (8.5) ETR=erythematotelangiectatic rosacea; OTC=over the counter; PPR=papulopustular rosacea. a Due to a survey programming error, only a small portion of responses were captured. Although the panel vendor attempted to re-contact respondents to complete the question, re-contact rates were low. Caution should be taken when interpreting these results. O R I G I N A L R E S E A R C h

Articles in this issue

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - JUN 2017